XKRX
005500
Market cap189mUSD
Oct 08, Last price
20,100.00KRW
1D
1.41%
1Q
10.02%
Jan 2017
-42.16%
Name
Samjin Pharmaceutical Co Ltd
Chart & performance
P/E
10.53
P/S
0.82
EPS
1,909.49
Div yield, %
3.98%
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
5.62%
Revenues
309.13b
+0.25%
Net income
24.17b
-38.39%
CFO
22.23b
-41.73%
Dividend
Dec 29, 2025800 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
Key people
Seung Ju Choi
Co-Chairman · since 2021
Hyeon Nam Myung
Vice President · since 2021
Ji Hyeon Choi
Managing Director
Jae Rang Sung
Managing Director
Jeong Tae Ahn
Assistant Managing Director
Ji Seon Choi
Assistant Managing Director
Sang Jin Jeon
Assistant Managing Director
Jeong Yil Kim
Assistant Managing Director
Gyu Yil Lee
Assistant Managing Director
Gap Jin Oh
Assistant Managing Director
Su Nam Park
Assistant Managing Director
Byeong Wuk Sung
Assistant Managing Director
Ui Hwan Cho
Co-Chairman · since 2021
Gyu Seok Cho
Co-President, Co-Chief Executive Officer, Director · since 2025
Gyu Hyeong Cho
Vice President, Director · since 2024
Gi Yeong Goh
Non-Executive Independent Director
Sang Beom Han
Non-Executive Independent Director
Wan Gyun Hwang
Non-Executive Independent Director · since 2017
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||